Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Issue 2 (February 2015)

• Record Type: Journal Article
• Authors: Bednaruk-Młyński, Ewa; Pieńkowska, Joanna; Skórzak, Adam; Małkowski, Bogdan; Kulikowski, Waldemar; Subocz, Edyta; Dzietczenia, Justyna; Zalewska, Marta; Leśniewski-Kmak, Krzysztof; Zaucha, Renata; Wróbel, Tomasz; Zaucha, Jan M.
• Is Part Of: Leukemia & lymphoma. Volume 56:Issue 2(2015:Feb.)
• Page Start: 377
• Page End: 382
• Publication Date: 2015-02
• Subjects: Leukemia -- Periodicals; Lymphomas -- Periodicals; 616.99419
• DOI: 10.3109/10428194.2014.919635
• Languages: English
• ISSNs: 1042-8194

Abstract

<abstract> <title>Abstract</title> <p>We compared initial computed tomography (CT) and positron emission tomography (PET)/CT in 96 patients with Hodgkin lymphoma (HL), assessing the role of baseline PET/CT in stage migration and treatment selection. The number of patients with stage I, II, III and IV disease based on CT versus PET/CT was: 5 vs. 7, 49 vs. 37, 28 vs. 22 and 14 vs. 30, respectively. In 33 (34%) patients, PET/CT changed HL stage: 27 (28%) were upstaged and six (6.3%) downstaged. Upstaging was caused by detection of new extranodal involvements (47 sites in 26 patients): bone marrow (10 patients), spleen (five patients) and lung (two patients). In nine patients ≥ 2 further coexisting locations were detected. Downstaging resulted from the absence of fluorodeoxyglucose (¹⁸F-FDG) uptake in enlarged nodes (&gt; 15 mm) in the abdomen and pelvis. PET/CT modified HL stage in 34% of patients leading to treatment modification in the majority. Our results indicate that PET/CT should be mandatory in the initial staging of HL.</p> </abstract>